Well today (AH) AEGR is down about $11 so far today. FDA and DOJ problems. This stock is dead until this is resolved. So look into PLI for a real rocket over the next 12 months - still a bargain at 89 cents Canadian for a great play on pretty reliable play on orphan drugs with Billionaire partners.
So it appears that sales are starting up in Japan as the company stated:
Receipt of Rare Disease Drug Designation for lomitapide from Taiwan's Ministry of Health and Welfare which allows sales in Taiwan under a named patient program.
So about 10 Japanese patients in the study in the first quarter, then widening based on success.
UK & Germany sales are starting up now too.
It also looks like they will start the pediatric study as well.
This is the same guy (yassen_gregorivich) who said AEGR would be trading at $100 by end of 2013. Why does he keep talking?
Your nonsensical rantings rarely make any sense.
The CRMD was a quick look at what a spammer posted that instantly revealed he many flaws with it. I didn't go to their website or make trouble at all, I merely voiced my opinion to refute the off topic spammer. Nothing more. CRMD is a joke, much like you.
As for the time horizon for AEGR, you should check your 1970 data off Wikileaks and then go invest again based on that. That strategy has worked SO well for you in the past.
Talk about a rocket ship launch. ICPT hit it good this morning. Now the only question is, whether to sell that & buy back in to AEGR at these artificially low prices.
Yugo, what is your time frame for the 1200 to 6400 per share? It looks like you turned into some kind of grinch, #$%$ lover, Obamalover in regards to CRMD. What happened there? Did you short the stock at 5 cents and lose a whole bunch of money so you go to their website to create trouble? It's nice to know that you have a stable company with a deep pipeline with your AEGR holdings anyway. t
Opposite of Timber is LIFT OFF. Nice rise today.
Though seasoned veteran investors know that it is nothing more than market static.
Down one day, back up the next day.
A day traders dream to be sure!
What really matters is that we are $400/share a year from now.
I'm saying that it is max'ed out in regards to indications for which it is approved for now and that it will be extremely hard to get any further indications beyond what it is approved for. It has been out less than a year and you are telling me it's a great drug and what I'm saying is nonsense. Is Trovan, Omniflox, and a host of other great drugs really that great? t
I have seen lomitapide at work and I can tell you. It is a great drug! Whatever else you say is pure nonsense
Sentiment: Strong Buy
. Also, SB told me that he thought that Mipo was one of the safest drugs he had ever seen. Little by little even though GENZ blew it in regards to proper PR the truth will come out. Just like statins could cause CA to now statins may be part of treating CA things change and the markets have not recognized that AT ALL yet. t
A great disservice has been done to the public by giving off the attitude that this drug is just like a big strong brother to a statin:
They have for the most part max'ed out on their potential. Mr. Beer wants to keep on doing studies in the hope of finding more adults to use the drug on. In this day and age, like when political polls are plus-minus three percent accuracy I just don't see how Mr. Beer is going to get anywhere near the 1 to 350 K that they are hoping for in regards to prevalence for HoF . You couple that with the latest data on that one patient who took the j-drug at an average dose of 20mg per day for thirteen years and ended up with definite liver failure....for that reason I think that the peds studies that Mr. Beer wants to do are going to have to be three times bigger and five times longer than the adult study was that allowed the j-drug to get approved. They at AEGR went after lipidologists first and Mr. Beer admitted that they got out of the gate slower in regards to cardiologist who are in a ratio of probably 50:1 to lipidologists. You then have pricing pressures around the world with their goal to only sell their drug below 20% ROW to that price found in the US. It probably won't happen. Also, if it doesn't happen, the drug is still so expensive here it might make sense for Americans to travel overseas every six months to see a lipidologist overseas in regards to the prescription filling if their insurance would allow it. And the higher the price differential the greater the risk that this will happen Worse yet, if it goes for considerably less in Canada or Mexico that would make it that much more easier for patients to get prescriptions at a lower rate there. I myself would not ever take the drug knowing what I know with ISIS having Mipo as an alternative and the liver adaptation that I know is true with Mipo.......that ISIS said all along was true and it was never brought up by the FDA prelim committee. Also, SB told me that he thought tha
It had it's place it is outmoded for that use, or will be when the ApoCIII inhibitor and DGAT2 inhibitors come out. It is especially not suited for children as Mr. Beer seeks. t
The lady on lomitapide is alive and, presumably, happy, after 13 years of treatment. She would have been dead without lomitapide! The issue of liver damages may be important (I am not sure how much) for severely hypertriglyceridemic patients. However, today, I would rate Juxta as the still the best possible treatment also for these. For the homozygotes, liver damage is not a major issue.
Sentiment: Strong Buy
Now the lies really come out. You bought at $11 eh? Your total amount too I presume, and you sold all of your shares at 115 and bought them all back at 61 too? The stock is worth a risk, worth more than 11, but not worth 68 bucks a share. That 69-70 barrier is a tough nut to crack eh Yugo? That one lady treated for 13 years with juxta and who died from liver failure really only had a dose of about 20mg per day most of the time she was on the drug. Three things about that: 1)The drug won't probably safe long term for the doseages that Mr. Beer tricked everyone into thinking...like 40 to 60 mg per day, 2)The pediatric use IMO is almost an impossibility, or the studies will have to be three times as big and go five times as long as the flimsy study that AEGR ran for adults, 3)And the drug will never see the light of day in regards to using it for severe hypertriglyceridemia. The second ZAP, ZAP2 will be coming sometime in late Feb. t
Uh, yeah. I bought at $11 now it is at $68. It's up 600%.
Oh, you were trying to point out that it had ONE down day. No problem there. It is STILL up more than 600% even AFTER that one down day.
Yugo, you are dummy number one. The CEO is getting ready to recruit kids as he noted about it in his last CC. It won't work wait and see. Then you'll again be the one wanting government intervention like you and the ranger when you both wanted to call out the dogs when you thought you had me for inside info when the CEO put both feet hoping his mouth at the same time. Anyone can see that you are a constipated termite and you can't pass your boards when you spew out this KKK, Oboma stuff. You will be on a Missouri boat ride this year. No 6500 per share, man with one drug you can believe that. You are really dummy number one. Hope your wife can keep working so while you are just watching TV with your nose on the ground she can have some money coming in. t
Did you look that up on Wikipedia?
Just how do you know which patients the CEO is trying to recruit? That is non-public information, yet again, you pretend to know it.
Think about this. What happens to patients who don't get AEGR's medicine? Oh yeah - they DIE. Thanks, but most would rather deal with liver issues than dead-issues.